Ulcerative colitis market was valued at $6.2 billion in 2020, and is estimated to reach $10.8 billion by 2030, growing at a CAGR of 5.7% from 2021 to 2030. Ulcerative colitis is an inflammatory bowel disease that affects the colon and rectum of the human body. The disease affects people of any age and most commonly it begins during adolescence and early adulthood, but it may also occur later in life. Ulcerative colitis is highly prevalent in the U.S., England, and northern Europe. The most commonly preferred treatment options for ulcerative colitis are traditional medications made of biologics and small molecules.
𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Key players that operate in the ulcerative colitis market include Abbott Laboratories, Ajinomoto, Astrazeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/3965
Factor that drives the ulcerative colitis market growth include increase in number of inflammatory bowel disease. In addition, rise in number of ulcerative colitis incidences propels growth of the market. However, rise in burden of inflammatory bowel disease increases growth of the market. Furthermore, the Food and Drug Administration (FDA) aims to enhance availability of reliable and effective drugs to meet public health needs and increase access to treat consumers.
Moreover, rise in development of pharmaceutical and medical device industries and improvement in healthcare spending are anticipated to drive growth of the ulcerative colitis market. In addition, increase in development of new product launches led to rise in the healthcare sector, thereby propelling growth of the market.
Moreover, governments initiatives for development of new drugs and healthcare sector for manufacturing of ulcerative colitis drugs are the key factors that boost growth of the market.
For instance, in May 2018, Takeda Pharmaceutical Company Ltd. and Shire Plc. announced that Takeda had reached an agreement on the terms of proposed offer to acquire all of outstanding shares and future common shares of Shire Plc. In addition, in June 2019, Abbvie completed the acquisition of Allergan to expand its product portfolio to offer extensively advanced treatments for patients. Allergan launched a monoclonal antibody called brazikumab, which is used in the treatment of ulcerative colitis. Thus, increase in development of new drugs drives the substantial growth of the ulcerative colitis market size during forecast period.
𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/3965
𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘
- By disease type, the mild UC segment was the highest contributor to the market in 2020.
- On the basis of molecule type, the small molecule segment dominated the market in 2020, and is expected to continue this trend during the forecast period.
- On the basis of route of administration, the oral segment dominated the market in 2020, and is expected to continue this trend during the forecast period
- Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060